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In the past three decades the European eel Anguilla anguilla experienced up to 26 
99% decline in recruitment in some parts of its distribution range, thus breeding 27 
in captivity is nowadays considered key in order to save this species. With this in 28 
mind, obtaining high quality gametes is fundamental, as is the ongoing study of 29 
new hormonal treatments in order to improve current methods. Therefore, the 30 
aim of this research study was i) to assess the effect of two hormonal treatments 31 
(OVI, a recombinant α-choriogonadotropin; and VET, a human chorionic 32 
gonadotropin purified from female urine) on the reproductive performance of 33 
European eel males, and, after choosing the best hormone, ii) to compare the 34 
effects of three doses in order to cut the costs of artificial maturation. 35 
Our results indicated that the type of hormone used (recombinant vs purified 36 
gonadotropins) significantly affected the progression of spermiation in European 37 
eel males, and that the recombinant hormone (OVI) produced better results in 38 
terms of sperm quantity and quality in most of the weeks of the treatment, 39 
remaining thus an effective treatment to induce spermiation in this species. On 40 
the other hand, in terms of the doses experiment, our results showed that from 41 
the lowest to the highest dose (0.25 to 1.5 IU/g fish) all the treatments were able 42 
to induce the whole spermiation process. However, a weekly dose of 1.5 IU/g fish 43 
of recombinant hormone (OVI) was necessary in order to provide a notable 44 
amount (volume and density) of high quality (motility and velocity) samples 45 
throughout the treatment. 46 
Finally, the economic analysis demonstrated that the recombinant hormone (OVI, 47 
1.5 IU/g fish) had a greater profitability than the other treatments, making it 48 
possible to obtain high-quality sperm for a lower price. In this context, and 49 
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considering the fact that in the first few weeks of any hormonal treatment there is 50 
no high-quality sperm production, long-term hormonal therapies are necessary in 51 
order to lessen the cost of high-quality European eel sperm. 52 
 53 
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1. Introduction 56 
The European eel (Anguilla anguilla) is an important species for European 57 
aquaculture (5000 tonnes per year, FAO 2014), being highly appreciated both in 58 
the European and Asian markets. However, its current production still consists in 59 
the fattening of eels captured in the natural environment, due to the fact that it is 60 
not yet possible to reproduce eels in captivity. In addition, a drastic decrease has 61 
been observed in the number of wild European eels migrating from Europe and 62 
North Africa to the spawning sites in the Atlantic Ocean, leading to the species 63 
being included in the IUCN red list as critically endangered. Therefore, breeding 64 
in captivity is postulated as a key alternative in order to save this species, which 65 
will help to reduce the pressure on natural populations, it will facilitate the supply 66 
to the eel farms, and it will allow repopulation in areas where those that historically 67 
were located the eel. 68 
Although in some fish species reproduction in captivity can be controlled 69 
exclusively by environmental factors (Rocha et al., 2008), sometimes it is 70 
impractical or even impossible to simulate the environmental conditions in which 71 
sexual maturation happens (i.e. depth, pressure, spawning migration, etc.), so 72 
the use of exogenous hormones is the only effective way of inducing reproduction 73 
(reviewed by Mylonas et al., 2010, 2017). This is the case of the eel species 74 
(Anguilla spp.), as they do not mature spontaneously in captivity, and the 75 
maturation of both males and females must be induced with long-term hormonal 76 
treatments (Asturiano et al., 2005; Lokman et al., 2016; Ohta et al., 1997; 77 
Sorensen and Winn, 1984). 78 
In the case of European eel males, human chorionic gonadotropin (hCG) has 79 
been the most widely used hormone for achieving spermiation, but it has been 80 
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administered to the animals in several different formats (Gallego et al., 2012). 81 
The first studies date back to the middle of the 20th century, where gonadal 82 
maturation in eel males was induced by intraperitoneal injections of urine from 83 
pregnant women (Fontaine, 1936). At the end of the century, several companies 84 
were able to isolate hCG from female urine, so the induction of spermiation of this 85 
species became a much more simple and standardized process (Dollerup and 86 
Graver, 1985; Khan et al., 1987; Pérez et al., 2000). Studies from the beginning 87 
of the 21st century served to develop and optimize hormonal treatments based 88 
on purified hCG, optimazing the sperm production and sperm quality  through 89 
weekly intraperitoneal injections of 1.5 IU/g fish (Asturiano et al., 2006). However, 90 
both the duration of the spermiation period (limited in time) and the interruption 91 
of the availability of hCG (in its purified form) in the market meant that new studies 92 
addressing the use of alternative hormones became necessary. In this context, 93 
the arrival of human recombinant gonadotropins (hCGrec, produced by 94 
recombinant DNA technology) became an effective alternative due to the similar 95 
structure of the native human hormone, and throughout the last few years they 96 
have yielded good results (Gallego et al., 2012). Nevertheless, the effectiveness 97 
of treatments based on hCGrec apparently depends on the batch of hormones 98 
used, and sometimes it is possible to find groups of animals where although 99 
gonadal maturation occurs, the sperm quality parameters (such as motilities and 100 
velocities) are not good enough for scientific or aquaculture purposes. Recently, 101 
new studies using specific (native) European eel recombinant gonadotropins 102 
were also able to induce spermiation in eel males, but the sperm volume and 103 
motility results were low for carrying out fertilization trials (Peñaranda et al., 104 
2018). In addition, the production of these native hormones is a tedious and 105 
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sophisticated process that can only be carried out by companies, thus the end 106 
cost of the hormones is prohibitive for many research groups. 107 
Therefore, studies into alternative hormonal treatments must be ongoing in order 108 
to improve current methods to date. With this in mind the aim of this work was i) 109 
to assess the effect of two hormonal treatments (recombinant vs purified mammal 110 
gonadotropins) on the reproductive performance of European eel males and, 111 
after choosing the best treatment, ii) to compare three different hormone doses 112 
in order to cut the costs of artificial maturation in this species both for fish farms 113 
and laboratories. 114 
 115 
2. Materials and methods 116 
2.1. Fish maintenance  117 
Eel males from the fish farm Valenciana de Acuicultura, S.A. (Puzol, Valencia; on 118 
the east coast of Spain) were moved to our facilities, in the Aquaculture 119 
Laboratory at the Universitat Politècnica de València, Spain. The fish were 120 
distributed into aquaria equipped with separate recirculation systems, 121 
thermostats/coolers, and covered to reduce the light intensity and fish stress. The 122 
eels were gradually acclimatized to sea water (salinity 37 ± 0.3 g/l) over the 123 
course of one week, and later once a week they were anaesthetized with 124 
benzocaine (60 ppm) and weighed to calculate the individual doses of the 125 
hormone, which were then administered by intraperitoneal injection.  126 
The fish were not fed throughout the experiment and were handled in accordance 127 




2.2. Experimental design  130 
Experiment 1. Hormonal treatments: recombinant vs purified gonadotropins 131 
Twenty adult eel males (mean body weight 107.9±1.6 g) were equally and 132 
randomly distributed into two 150-L aquaria (10 males per treatment) where they 133 
underwent two hormonal treatments: OVI (a recombinant α-choriogonadotropin 134 
produced in Chinese hamster ovary cells by recombinant DNA technology and 135 
marketed as Ovitrelle; Merck S.L., Madrid) and VET (purified human chorionic 136 
gonadotropin marketed as Veterin Corion; Divasa-Farmavic S.A., Barcelona).  137 
The VET hormone was dissolved in a saline serum (NaCl 0.9%) to obtain a 138 
concentration of 1 IU/µL serum. The OVI hormone was diluted to obtain a similar 139 
concentration. The hormones were injected weekly at a dose of 1.5 IU/g fish and 140 
were administered for 25 weeks. 141 
 142 
Experiment 2: Different doses of recombinant gonadotropin 143 
After choosing the recombinant gonadotropin (OVI) as the best hormone in terms 144 
of sperm quality and profitability, 30 adult eel males (mean body weight 102.3±3.7 145 
g) were equally and randomly distributed into three 150-L aquaria (10 males per 146 
treatment). Each group (aquarium) received a different hormonal treatment doses 147 
(OVI1.5: 1.5 IU/g fish; OVI0.75: 0.75 IU/g fish; or OVI0.25: 0.25 IU/g fish; 148 
respectively) with the final aim of reducing production costs. The hormone was 149 
diluted 1:1 (IU/µl) in saline solution (NaCl 0.9%) and the doses were administered 150 
weekly for 12 weeks. 151 
 152 
2.3. Sperm collection and sampling 153 
Sperm samples were collected weekly by the application of abdominal pressure 154 
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24 h after the administration of the hormone (following the protocol described by 155 
Pérez et al., (2000)), and taking special care to avoid contamination with faeces, 156 
urine and sea water. Samples were diluted 1:9 (sperm:extender) in P1 medium 157 
(D. S. Peñaranda et al., 2010) and kept in plastic tubes at 4 ºC until the sperm 158 
kinetic analyses, which were carried out in the 2 hours following sperm collection. 159 
Sperm volume was previously measured using graduated tubes and sperm 160 
density was determined by a CASA system (see next section). 161 
 162 
2.4. Evaluation of sperm motility and kinetic parameters 163 
Samples were activated by mixing 0.5 µl of P1-diluted sperm with 4.5 µl of artificial 164 
sea water (Aqua Medic Meersalz, 37 g/l, with 2% BSA (w/v), pH adjusted to 8.2). 165 
All the motility analyses were performed in triplicate using the motility module of 166 
ISAS (Proiser R+D, S.L.; Paterna, Spain) as described by Gallego et al. (2013). 167 
The chamber used in all the experiments was a SpermTrack-10® (Proiser, 168 
Paterna, Spain) with a 10x negative contrast phase lens in a Nikon Eclipse (E-169 
400) microscope. 170 
The parameters considered in this study were total motility (MOT, %); progressive 171 
motility (pMOT, %), defined as the percentage of spermatozoa which swim 172 
forwards in 80% of a straight line; curvilinear velocity (VCL, in µm/s), defined as 173 
the time/average velocity of a sperm head along its actual curvilinear trajectory; 174 
average path velocity (VAP, µm/s), defined as the time/average of sperm head 175 
along its average spatial trajectory; and straight line velocity (VSL, µm/s), defined 176 
as the time/average velocity of a sperm head along the straight line between its 177 
first detected position and its last position. Spermatozoa were considered motile 178 
if their progressive motility had a VSL over 10 µm/s. 179 
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In order to perform an in-depth analysis of the results, sperm samples were 180 
classified into three classes based on the percentage of motile spermatozoa 181 
provided by the CASA system: Class I (C-I) = 0-25% of motile cells; Class II (C-182 
II) = 26-50% of motile cells; and Class III (C-III) = 51-100% of motile cells.  183 
 184 
2.5. Economic analysis 185 
To analyse the economic profitability of each hormonal treatment (both in 186 
experiment 1 and 2) three factors were taken into account: i) the price of the 187 
hormone; ii) the total amount of hormone used (dose) throughout the whole 188 
treatment; and iii) the total volume of sperm of the highest motility class (C-III) 189 
produced by each treatment. The aim was essentially to relate the investment 190 
made with the level of good quality sperm produced by each hormonal treatment. 191 
 192 
2.6. Statistical analysis 193 
The mean and standard error were calculated for all sperm parameters (volume, 194 
density, motility and the rest of the kinetic parameters). Shapiro-Wilk and Levene 195 
tests were used to check the normality of data distribution and variance 196 
homogeneity, respectively. A two-way ANOVA was used to analyze the sperm 197 
production and quality parameters. Significant differences were detected when 198 
p-value < 0.05. All statistical analyses were performed using the statistical 199 
package SPSS version 19.0 for Windows software (SPSS Inc., Chicago, IL, 200 
USA). 201 
 202 
3. Results 203 
3.1. Experiment 1. Hormonal treatments: recombinant vs purified gonadotropins  204 
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The sperm production parameters are shown in Figure 1. Most of the OVI-treated 205 
fish (90%) started to produce sperm in the 6th week of treatment, while only 60% 206 
of VET-treated fish generated sperm in this week (Figure 1A). From the 12th to 207 
the 18th week, the VET treatment generated higher percentages of spermiating 208 
males (90-100%) than the OVI treatment (70-80%) and, finally, the decreasing 209 
percentages of spermiating males were similar in the last few weeks (19th to 25th) 210 
in both treatments. 211 
Regarding volume, there was an increasing trend from the beginning to the end 212 
(Figure 1B) in both treatments. Volume values were generally higher in OVI 213 
treated males, although statistical differences were only found in weeks 8 and 9, 214 
probably due to the high dispersion of data found in the OVI-treated males during 215 
the last few weeks. Density values were slightly higher in VET treated males from 216 
weeks 11 to 21, but significant differences were only found in weeks 13 and 15 217 
(Figure 1C). 218 
Regarding the sperm quality parameters, OVI males showed higher motilities 219 
than VET males during the first few weeks of treatment (Figures 2A and 2B), 220 
reaching maximum values of 76 and 45% of MOT and pMOT, respectively. 221 
However, VET-treated males showed a marked rise from week 12 (with 77 and 222 
35% of MOT and pMOT, respectively), and motility parameters were similar for 223 
both hormones until the end of the treatment, with values remaining over 50% in 224 
the 25th week. The sperm velocities (Figures 2C, 2D and 2E) showed a similar 225 
pattern to the motility traits: OVI-treated males showed higher velocities (VCL, 226 
VSL and VAP) than VET-treated males during the first few weeks of the 227 
treatment, but the kinetic values were similar in both hormone treatments from 228 
the 12th week until the end of the treatment. 229 
11 
 
Finally, when the volume and the sperm motility classes were considered 230 
simultaneously (Table 1, experiment 1), it was observed that the OVI treatment 231 
displayed better total volume results (with volume values over 500 mL of C-III 232 
sperm) than the VET treatment, which yielded total volume values of around 200 233 
mL of C-III sperm. In addition, in terms of the production of high quality sperm 234 
week-by-week (Figure 3), the OVI treatment showed a higher number of weeks 235 
(8th, 9th, 10th, 12th, 22th, 23th, 24th and 25th) providing higher volumes of good 236 
quality sperm (C-III) than the VET treatment. 237 
Regarding the economic analysis, the investment needed to obtain mature males 238 
was quite different in each hormonal treatment (Table 2; experiment 1). The VET 239 
treatment investment was smaller, at 0.69 €/week per male, nevertheless, 240 
although the OVI treatment required a higher investment per male (1.17 €/week 241 
per male), the total volume of class III sperm obtained from OVI-treated males 242 
was much higher than VET males (Table 1). Therefore, the final profitability of 243 
this hormone was higher in OVI treated males, where it was possible to obtain 1 244 
mL of the highest quality sperm (C-III) for a lower price (0.44 €/mL). The other 245 
hormone (VET) produced worse economic results because it was necessary to 246 
invest 0.86 € to obtain 1 mL of good quality (C-III) sperm. 247 
 248 
3.2. Experiment 2: Different doses of recombinant gonadotropin 249 
In terms of the sperm production parameters (Figure 4), all the doses of 250 
recombinant gonadotropin (OVI) were able to induce high percentages of 251 
spermiating males (around 80%) during most of the weeks of treatment. 252 
However, the OVI0.25 group produced the lowest percentages of spermiating 253 
males during the last few weeks (around 60%). 254 
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Regarding volume, an increasing trend from the beginning to the end was seen 255 
in all three treatments (Figure 4B). The volume values were generally higher in 256 
the OVI0.25 group, but statistical differences were only found in week 8 and 10. 257 
On the contrary, density patterns were slightly higher in males treated in the 258 
OVI1.5 group, and significant differences were found from the 9th and 12th week 259 
(Figure 4C). 260 
Concerning sperm quality parameters, OVI.1.5-treated males provided samples 261 
with statistical higher values of MOT and pMOT throughout almost all the 262 
treatment (Figures 5A and 5B), reaching maximum values of 72 and 46%, 263 
respectively. Conversely, medium and low doses (OVI0.75 and OVI0.25) provided 264 
samples which only showed maximums of 30 and 20% of MOT, respectively. The 265 
spermatozoa velocities (Figures 5C, 5D and 5E) showed similar patterns to those 266 
of motility, and OVI1.5-treated males showed higher velocities with significant 267 
differences (VCL, VSL and VAP) throughout most of the treatment. 268 
Finally, when the volume and the sperm motility classes were evaluated 269 
simultaneously (Table 1, experiment 2), it was observed that the highest dose 270 
(OVI1.5) was the only treatment able to produce acceptable volumes (near 100 271 
mL) of good quality (C-III) sperm. On the contrary, medium and low doses (OVI0.75 272 
and OVI0.25) provided large volumes of bad quality sperm (C-II especially and C-273 
I), which represented more than 95% of total volume production for each 274 
treatment. In addition, when looking at the production of high quality sperm week-275 
by-week, the OVI1.5 treatment showed a higher number of weeks (8th, 9th, 10th, 276 
11th and 12th) providing higher volumes of C-III sperm than the other treatments 277 
(Figure 6). 278 
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Regarding the economic analysis, the investment needed to obtain mature males 279 
was quite different in each hormonal treatment (Table 2, experiment 2). The 280 
OVI1.5 treatment required the highest investment per male per week (1.17 €), 281 
while an investment of 0.58 and 0.19 € were necessary in order to mature fish 282 
with OVI0.75 and OVI0.25, respectively. However, the total volume of class III sperm 283 
obtained from OVI1.5-treated males was much higher than that produced by 284 
OVI0.75 and OVI0.25 males (Table 1), so the final profitability of the standard dose 285 
(OVI1.5) was the highest, with it being possible to obtain 1 mL of the highest quality 286 
sperm (C-III) for the lowest price (1.78 €/mL). 287 
 288 
4. Discussion 289 
4.1. Hormonal treatments: recombinant vs purified gonadotropins  290 
The study of alternative hormonal treatments to improve both sperm production 291 
and quality parameters must be ongoing in order to enhance gonadal maturation 292 
in fish (Mylonas et al., 2017), specifically in species with serious reproductive 293 
problems, such as the European eel (Gallego et al., 2012; Peñaranda et al., 294 
2018). In the present study, our results indicated that the type of hormone used 295 
(recombinant vs purified gonadotropins) significantly affects the progression of 296 
spermiation in European eel males, with the recombinant hormone (OVI) 297 
producing better results in most of the weeks. 298 
First of all, it is important to note that sperm quantity and quality have become a 299 
key factor in controlled reproduction both for aquaculture and scientific purposes, 300 
thus reasonable volumes of high quality samples are necessary in order to 301 
fertilize the maximum number of eggs (Migaud et al., 2013; Tvedt et al., 2001). In 302 
this context, although both hormones (OVI and VET) were able to induce a high 303 
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percentage of spermiating males (>70%), there was a notable difference in sperm 304 
volume and density patterns between the treatments. In terms of volume, OVI-305 
treated males produced approximately twice (even triple) the volume than VET-306 
treated males in all the weeks, thus the final amount of sperm resulting from the 307 
OVI hormone was much higher than that produced by VET-treated males. In this 308 
context, Gallego et al. (2012) reported similar results in this species when using 309 
the recombinant hormone (OVI), where a purified hormone (from a different 310 
brand) used in that previous study yielded remarkable results (up to 8 mL). In 311 
addition to the volume, the density values provided by VET treated males in the 312 
present study were not high enough to compensate for the lower volumes 313 
produced by this hormone in most of the weeks, thus the recombinant hormone 314 
(OVI) was the best treatment according to both the sperm production parameters. 315 
Moreover, in addition to sperm quantity, sperm quality is a crucial factor in 316 
fertilization trials, and several kinetic parameters (characterizing sperm motility 317 
and velocity) are nowadays considered to be the best fish sperm quality 318 
biomarkers (Gallego and Asturiano, 2018). In experiment 1, both hormones 319 
yielded remarkable motility and velocity values during most of the treatment, 320 
although the recombinant hormone (OVI) was able to provide high quality 321 
samples during a greater number of weeks (18/20) than the purified hormone 322 
(12/20). In this context, it is noteworthy that an essential factor in European eel 323 
breeding captivity programs is the ability to obtain high quality sperm for a large 324 
number of weeks in order to synchronize egg production by the females (Butts et 325 
al., 2014; Tomkiewicz et al., 2013), thus the recombinant hormone (OVI) was 326 
identified as the best treatment according to the sperm quality indicators. 327 
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From a physiological point of view, the different responses found in eel males 328 
regarding the different hormonal treatments could be explained by the biological 329 
activity of each hormone: while the VET hormone was a native hCG hormone, 330 
purified and isolated from human urine (Birken et al., 1996), the OVI hormone 331 
was a recombinant version of endogenous hCG produced by recombinant DNA 332 
technology (Choi and Smitz, 2015). Even though both hormones (OVI and VET) 333 
act as analogues of the luteinizing hormone (LH), Basselt et al. (2005) reported 334 
that purified-hCG preparations contained a high number of urine derived protein 335 
contaminants as well as hCG related metabolites, whereas recombinant hCG 336 
was confirmed to be essentially intact hCG (free from contaminant proteins and 337 
with very low levels of oxidised hCG). Therefore, the different nature and origins 338 
of these hormones (with different degrees and types of glycosylation) could 339 
induce gonadal maturation in different ways, generating different patterns in 340 
sperm volume or density as seen in previous studies reported by Gallego et al. 341 
(2012). In addition, recents reports showed that new recombinant hCGs are 342 
available in the market (Pregnyl, Ovidrel, etc.), and they could be probably useful 343 
for gonadal maturation in fish due to the high degree of structural and functional 344 
similarity with the reference format Ovitrelle (Leao and Esteves, 2015; Thennati 345 
et al., 2018). 346 
On the other hand, new hormonal therapies using specific recombinant 347 
gonadotropins are being developed to induce spermiation in eel species. 348 
Although results in European eel has not been good enough for applying in 349 
aquaculture purposes (Peñaranda et al., 2018), recombinant Japanese eel LH 350 
induced a much higher amount of high-quality sperm when compared to hCG 351 
injections in this species (Ohta et al., 2017). In this context, studies into alternative 352 
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hormonal treatments must be ongoing in order to improve current methods for 353 
inducing the successful artificial maturation of endangered species, such as the 354 
European eel. 355 
To sum up, our results demonstrated that the progression of spermiation in 356 
European eel males was notably influenced by the hormone used. Recombinant 357 
gonadotropin (OVI) showed the best results in terms of both sperm production 358 
and quality parameters, becoming an effective treatment to induce spermiation in 359 
the European eel. 360 
 361 
4.2. Different doses of recombinant gonadotropin (OVI) 362 
In addition to the task of pursuing new hormones in order to extend the 363 
spermiation period and enhance sperm quality, attempts to optimize hormonal 364 
therapies are also a key premise to be applied in both scientific and aquaculture 365 
sectors. In this context, and once the most efficient hormonal treatment from 366 
experiment 1 had been chosen, the effects on the induction of spermiation of 367 
several doses of the recombinant hormone (OVI) were evaluated.  368 
Our results showed that from the lowest to the highest dose of the recombinant 369 
hormone (0.25 to 1.5 IU/g fish), all the treatments were able to induce the whole 370 
spermiation process. Previous studies reported that a single injection of hCG was 371 
enough to induce spermatogenesis and spermiation both in European and 372 
Japanese eel species (Khan et al., 1987; Miura et al., 1991), but a continuous 373 
supply of hormone was necessary to maintain both the sperm production and the 374 
sperm quality throughout the weeks (Asturiano et al., 2005). In this context, our 375 
results agree with these previous studies, and a periodic supply of hCG (even 376 
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using the lowest doses) was able to maintain the spermiation process over the 377 
weeks. 378 
Concerning the sperm production rates (volume and density), the OVI0.25 group 379 
surprisingly yielded the highest sperm volumes throughout the treatment, with 380 
values reaching close to 8 mL in the 10th week. However, sperm density was 381 
lower in this group (OVI0.25) compared to the other two groups where higher 382 
recombinant hormone doses were injected (OVI0.75 and OVI1.5), thus the total 383 
amount of spermatozoa (volume x density) produced weekly was similar for all 384 
treatments. This density-volume pattern has already been described in other 385 
species, and this effect seems to be controlled by the maturation inducing 386 
steroids (MIS) which regulate the final stages of sperm maturation (Asturiano et 387 
al., 2002; Schulz et al., 2010). In this context, high densities would usually be 388 
linked to small volumes and conversely, low densities would need to be 389 
compensated by high sperm volumes. In addition, the density data yielded in this 390 
study using the standard doses of recombinant hCG (1.5 IU/g fish) agree with 391 
previous values obtained by administering the recombinant hormone in this 392 
species (Gallego et al., 2012), but density data were significantly higher than 393 
those obtained using purified hormone a decade ago (Asturiano et al., 2006; 394 
Pérez et al., 2000). 395 
On the other hand, and concerning the sperm quality parameters, notable 396 
differences were found between the treatments. In this context, only the group 397 
with the highest dose (OVI1.5) was able to generate samples with acceptable 398 
motility values from the 8th-9th weeks until the end of the treatment, while OVI0.25- 399 
and OVI0.75-treated males produced bad quality sperm (<35% of motility) in all the 400 
weeks. This low response in terms of motility in the groups receiving the lowest 401 
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doses could be due to a hormonal failure in the maturation process. In this sense, 402 
an insufficient weekly dose of gonadotropin could generate a deficient production 403 
of steroidogenic enzymes, which in turn would produce a low production of the 404 
steroids involved in gonadal maturation, therefore causing a poor production of 405 
good quality sperm (Jamalzadeh et al., 2014; Peñaranda et al., 2010; Schulz and 406 
Miura, 2002). Throughout the bibliography, the most common dose applied in fish 407 
has been 1 IU/g fish, but doses are usually species-dependent, varying from 0.15 408 
IU/g fish in pikeperch (Sander lucioperca) (Falahatkar and Poursaeid, 2014) to 409 
50 IU/g fish in silver perch (Leiopotherapon plumbeus) (Denusta et al., 2014). 410 
Considering European eel references, previous experiments carried out a decade 411 
ago also showed that doses of 0.75 IU/g fish were unable to provide high quality 412 
samples throughout the treatment, as per this study. However, a dose of 1.5 IU/g 413 
fish of purified hCG administered every 2 weeks provided a greater number of 414 
samples but of a similar quality (Asturiano et al., 2005), given more chances for 415 
carrying out hatchery operations related to fertilization trials. 416 
To sum up, our results have demonstrated that in order to achieve a successful 417 
maturation process in the European eel, a minimum dose of 1.5 IU/g fish of 418 
recombinant hCG administered weekly is necessary, inducing the production of 419 
reasonable volumes of high quality sperm samples. 420 
 421 
4.3. Economic analysis for the different hormones and doses 422 
From a biological point of view, the best hormonal treatment should provide a 423 
large amount (volume and density) of high quality (motility and velocity) samples 424 
for as many weeks as possible. However, from an economic point of view, a 425 
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reduction in the costs of hormonal therapies is essential in order to obtain 426 
affordable and more effective treatments (Mylonas et al., 2017). 427 
In the present study, the economic performance of the treatments was assessed 428 
by taking into account both the economic investment made (type, price and dose 429 
of hormone) and the total volume of high-quality sperm generated by each 430 
treatment. In experiment 1 and concerning high-quality sperm price, the 431 
recombinant hormone (OVI) generated the best results throughout the 432 
experiment, improving the performance yielded by the purified hormone (VET). 433 
In this context, and despite the fact that the investment required for maturating 434 
males using the recombinant hormone was almost double that of the purified 435 
gonadotropin (1.17 vs 0.69 €/male per week, respectively), the large amount of 436 
high-quality sperm produced by OVI-treated males (triple that of VET-treated 437 
males) meant a greater profitability, making it possible to obtain high-quality 438 
sperm for half the price (0.44 €/mL) of the purified hormone (0.86 €/mL). These 439 
results agree with previous studies carried out by Gallego et al. (2012), where 440 
recombinant hCG also generated better economic performances (0.5 €/mL) than 441 
gonadotropins purified from pregnant women and mares (0.72 and 1.8 €/mL, 442 
respectively). 443 
Moreover, the analysis of the economic return of the different doses used in 444 
experiment 2 yielded interesting results. Although the highest (OVI1.5) and the 445 
lowest dose (OVI0.25) of recombinant hormone generated similar economic 446 
performance in terms of high-quality sperm price (1.78 and 1.85 €/mL, 447 
respectively), the total C-III volume generated by OVI0.25 was too low (2.5 448 
mL/week) for a sustainable application in eel aquaculture, including large-scale 449 
fertilizations. In addition, when comparing the results of the economic profitability 450 
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of the same hormone (OVI) and dose (1.5 IU/g fish) from experiments 1 and 2, 451 
the results were notably different: the recombinant hormone showed a much 452 
better economic performance in experiment 1 (0.44 €/mL) than in experiment 2 453 
(1.78 €/mL). This difference can be explained by the large-scale production 454 
concept, where the cost advantages obtained by applying a different scale of 455 
operation (in this case 25 vs 12 weeks for experiment 1 and 2, respectively) 456 
decrease the cost per unit of output (high-quality sperm). In fact, when the 457 
economic profitability of experiment 1 was calculated just for the first 12 weeks, 458 
the economic performance of OVI was lower (1.06 €/mL) than for values obtained 459 
in the same experiment for 25 weeks (0.44 €/mL). Thus, because during the first 460 
few weeks of any hormonal treatment there is no high-quality sperm production, 461 
long-term hormonal therapies are necessary in order to lessen the cost of 462 
production of high-quality European eel sperm. 463 
Finally, and linking the production of large amount (volume and density) of high-464 
quality (motility and velocity) sperm samples to the essential hatchery tasks such 465 
as in vitro fertilization trials (IVF), Butts et al. (2014) showed that the sperm to 466 
egg ratio became a critical step towards establishing successful in vitro 467 
fertilization protocols. In this context, and taking into account the optimum value 468 
of sperm:egg ratio reported in this species (1:25,000), a large amount of eggs 469 
(approx. 10 million per week) could be fertilized using a batch of 10 males induced 470 
with recombinant hCG (1.5 IU/g fish). 471 
 472 
5. Conclusions 473 
In conclusion, this study shows that the type of hormone used significantly 474 
affected the progression of spermiation in European eel males, and the 475 
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recombinant hormone (Ovitrelle at 1.5 IU/g fish) produced the best results in 476 
terms of sperm quantity (volume and density) and quality (motility and velocity). 477 
In addition, the economic analysis demonstrated that the recombinant hormone 478 
had a greater profitability than the other treatments, hence becoming an effective 479 
method to induce the spermiation process in this species with the aim to provide 480 
high quality samples during a great number of weeks 481 
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Table legends 630 
Table 1. Total sperm volumes (mL) recovered from the different hormonal 631 
treatments of experiment 1 (OVI and VET; 1.5 IU/g fish) and experiment 2 (OVI1.5: 632 
1.5 IU/g fish; OVI0.75: 0.75 IU/g fish; and OVI0.25: 0.25 IU/g fish) for each sperm 633 
motility class (CI-CIII). 634 
 635 
Table 2. Profitability of hormonal treatments of experiment 1 (OVI and VET; 1.5 636 
IU/g fish) and experiment 2 (OVI1.5: 1.5 IU/g fish; OVI0.75: 0.75 IU/g fish; and 637 
OVI0.25: 0.25 IU/g fish) in relation to economic investment and production of high-638 
quality (Class III) sperm.  639 
28 
 
Table 1. 640 
  Experiment 1 (25 weeks)  Experiment 2 (12 weeks) 
Sperm Class  OVI VET  OVI1.5 OVI0.75 OVI0.25 
C-I  29.7 14.7  29.9 199.6 206.5 
C-II  45.1 85.0  26.5 15.8 94.4 
C-III  544.9 201.4  99.0 13.7 15.9 
  641 
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Table 2. 642 
   Experiment 1 (25 weeks)  Experiment 2 (12 weeks) 
   OVI VET  OVI1.5 OVI0.75 OVI0.25 
Dose IU/g fish  1.5 1.5  1.5 0.75 0.25 
Hormone price €/IU  0.008 0.005  0.008 0.008 0.008 
aDose price €/g fish  0.012 0.007  0.012 0.006 0.002 
bInvestment/male €/male  1.17 0.69  1.17 0.58 0.19 
cC-III sperm price €/mL  0.44 0.86  1.78 6.44 1.85 
 643 
a Dose x Hormone Price 644 
b Investment to maturate one male (100 g approx.) per week. 645 
c Total investment (€) / Total C-III sperm volume (mL).  646 
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Figure captions 647 
Figure 1. Evolution of sperm production parameters throughout the hormonal 648 
treatments (OVI and VET; 1.5 IU/g fish): A) Percentage of spermiating males; B) 649 
Sperm volume; and C) Sperm density. Data are expressed as mean ± SEM and 650 
asterisks indicate significant differences between treatments at each week of 651 
treatment. 652 
 653 
Figure 2. Evolution of sperm quality parameters throughout the hormonal 654 
treatments (OVI and VET; 1.5 IU/g fish): A) Percentage of motile cells; B) 655 
Percentage of progressive motile cells; C) Curvilinear velocity; D) Rectilinear 656 
velocity; and E) Average path velocity. Data are expressed as mean ± SEM and 657 
different letters indicate significant differences between treatments at each week 658 
of treatment.  659 
 660 
Figure 3. Percentage of sperm volume from each motility class (I-III) in each 661 
week throughout the different hormonal treatments: A) OVI and B) VET.  662 
Motility classes: Class I = 0- 25%; Class II = 26-50%; and Class III >50% of motile 663 
cells. 664 
 665 
Figure 4. Evolution of sperm production parameters throughout the different 666 
hormonal doses of OVI treatment (OVI1.5: 1.5 IU/g fish; OVI0.75: 0.75 IU/g fish; 667 
and OVI0.25: 0.25 IU/g fish): A) Percentage of spermiating males; B) Sperm 668 
volume; and C) Sperm density. Data are expressed as mean ± SEM and different 669 




Figure 5. Evolution of sperm production parameters throughout the different 672 
hormonal doses of OVI treatment (OVI1.5: 1.5 IU/g fish; OVI0.75: 0.75 IU/g fish; 673 
and OVI0.25: 0.25 IU/g fish): A) Percentage of motile cells; B) Percentage of 674 
progressive motile cells; C) Curvilinear velocity; D) Rectilinear velocity; and E) 675 
Average path velocity. Data are expressed as mean ± SEM and different letters 676 
indicate significant differences between doses at each week of treatment. 677 
 678 
Figure 6. Percentage of sperm volume from each motility class (I-III) in each 679 
week throughout the different hormonal doses OVI treatment: A) OVI1.5: 1.5 IU/g 680 
fish; B) OVI0.75: 0.75 IU/g fish; and C) OVI0.25: 0.25 IU/g fish. 681 
Motility classes: Class I = 0- 25%; Class II = 26-50%; and Class III >50% of motile 682 
cells. 683 
  684 
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Figure 1. 685 






























































Figure 2. 687 
















































































































Figure 3. 689 
 690 
  691 
Weeks of treatment









































Figure 4. 692 
 693 



































































































































































































































































5 6 7 8 9 10 11 12
20
40
60
80
100 C
